Avri Havron

Avri Havron is a biotech executive with over two decades of experience in the industry. Avri currently serves on the board of CollPlant, a company that manufactures and develops drugs purified from human plasma. Prior to their current role, Havron served as the Chief Technology Officer of Clal Biotechnology Industries, a holding company that invests in and supervises several health care startup companies. Avri also served as the Chief Executive Officer of Prolor Biotech from 2005 to 2013, during which time the company developed long-acting versions of therapeutic recombinant human proteins. In 2013, Prolor Biotech was acquired by OPKO Health and Havron served as Vice President of Manufacturing & Process Development at BioTechnology General from 1987 to 1999.